Results 101 to 110 of about 12,515 (211)

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase [PDF]

, 2003
Thomas B. Sneed, Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Mary Beth Rios, B. Nebiyou Bekele, Xian Zhou, Debra Resta, William Wierda, Stefan Faderl, Francis J. Giles, Jorge E. Cortés   +11 more
openalex   +1 more source

Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status [PDF]

, 2003
Debra Resta, Martin S. Tallman, Mary Beth Riley, John L. Frater, Brian J. Druker, LoAnn Peterson, Daina Variakojis, Mary Ann Hrisinko   +7 more
openalex   +1 more source

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis. [PDF]

Front Syst Neurosci, 2022
Perkins ME, Girard BM, Campbell SE, Vizzard MA.   +3 more
europepmc   +1 more source

Imatinib Mesylate Induces Necroptotic Cell Death and Impairs Autophagic Flux in Human Cardiac Progenitor Cells. [PDF]

Int J Mol Sci, 2022
Walmsley R, Steele DS, Ellison-Hughes GM, Papaspyros S, Smith AJ.   +4 more
europepmc   +1 more source

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia [PDF]

, 2003
Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Francis J. Giles, Mary Beth Rios, Jianqin Shan, Laurie Letvak, Deborah A. Thomas, Stefan Faderl, Alessandra Ferrajoli, Jorge E. Cortés   +12 more
openalex   +1 more source

Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi

Pakistan Armed Forces Medical Journal
Objective: To find the frequency of haematological response in patients of chronic myeloid leukaemia (Chronic Phase) after three months of Imatinib Mesylate therapy, presenting to CMH Rawalpindi Study Design: Cross-sectional study.
Anil Babar, Riaz Ahmed, Ahmed Raza, Zulfiqar Ali Amin, Muhammad Nadeem Piracha, Anum Zargham, Ibtisam Idrees   +6 more
doaj   +1 more source

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy [PDF]

, 2003
Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman, Heather C. Flynn, Sarah F. Paternoster, Brandon M. Shearer, Terra L. Reeder, Chin‐Yang Li, Nicholas C.P. Cross, Jan Cools, D. Gary Gilliland, Gordon W. Dewald, Ayalew Tefferi   +12 more
openalex   +1 more source

Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase

, 2002
Hagop M. Kantarjian, Jorge E. Cortés, Susan O’Brien, Francis J. Giles, Maher Albitar, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia‐Manero, Deborah A. Thomas, Debra Resta, Moshe Talpaz   +11 more
openalex   +1 more source

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells [PDF]

, 2003
Su Chu, Melissa Holtz, Mamta Gupta, Ravi Bhatia   +3 more
openalex   +1 more source

Imatinib Mesylate-Loaded Rosin/Cinnamon Oil-Based In Situ Forming Gel against Colorectal Cancer Cells. [PDF]

Gels, 2022
Khaing EM, Intaraphairot T, Mahadlek J, Okonogi S, Pichayakorn W, Phaechamud T.   +5 more
europepmc   +1 more source